tradingkey.logo

Bristol Myers Squibb Says Sotyktu Well-Tolerated Compared To Placebo And Apremilast

ReutersMar 8, 2025 2:08 PM

- Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB PRESENTS LATE-BREAKING DATA FROM PHASE 3 POETYK PSA-2 TRIAL DEMONSTRATING SUPERIORITY OF SOTYKTU (DEUCRAVACITINIB) COMPARED WITH PLACEBO IN ADULTS WITH PSORIATIC ARTHRITIS

  • BRISTOL-MYERS SQUIBB CO - SOTYKTU WELL-TOLERATED COMPARED TO PLACEBO AND APREMILAST

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI